Evidence map›Paper›PMID 42687201›Full record

ArticleExperimental hematology & oncology2026

Clinical outcomes and molecular features of CEBPA-mutated MPAL: a multi-center case series.

Yirong Wu, Weijie Luo, Na An, Xiaohan Zhang, Jianyun Li, Yixuan Cao, Yunxin Zeng, Peng Ke, Lu Liu, Linlin Yang and 11 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yirong Wu *Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Weijie Luo *Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Na An *Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Xiaohan Zhang *Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Jianyun LiHematology Department, People's Hospital of Shenzhen Bao an District, Shenzhen, 518000, China.
Yixuan CaoDepartment of Hematology, Shenzhen People's Hospital, Shenzhen, 518000, Guangdong, China.
Yunxin ZengDepartment of Hematology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, 518000, China.
Peng KeDepartment of Hematology, Shenzhen People's Hospital, Shenzhen, 518000, Guangdong, China.
Lu LiuDepartment of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Linlin YangDepartment of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Changru LuoDepartment of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Shiyu ChenDepartment of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Sitian YangDepartment of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Haoyu PengDepartment of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Xiaoqing LiDepartment of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Jingchao FanDepartment of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Rujiao DongDepartment of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Bingbing WenDepartment of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Xin DuDepartment of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China. duxingz@medmail.com.cn.
Lixin WangDepartment of Hematology and Oncology, Hematology Institution, Base for International Science and Technology Cooperation, Carson Cancer Stem Cell Vaccines R&D Center, International Cancer Center, Shenzhen University General Hospital, International Cancer Center, Haoshi Cell Therapy Institute of Shenzhen University, Shenzhen University Medical School, Shenzhen University, Xueyuan AVE 1098, Shenzhen, 518000, China. wanglixin1991@sohu.com.
Guangyang WengDepartment of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China. laifuzhixin@163.com.

Funding

Shenzhen Clinical Research Center for hematologic disease 20230731103645009Shenzhen Science and Technology Program JCYJ20230807115302005Shenzhen Second People's Hospital Clinical Research Fund of Shenzhen High-level Hospital Construction Project Grant No. 20243357004
6 · The paper itself

Abstract

Mixed phenotype acute leukemia (MPAL) is rare and aggressive, with no standard therapy. CEBPA mutations define favorable-risk AML, but their significance in MPAL is unknown. We reviewed eight CEBPA-mutated MPAL patients from five Chinese centers. Four received allo-HSCT in first complete remission and all remained alive and relapse-free (median follow-up of 24.0 months). Among four non-transplanted patients, three died (one refractory, two relapsed). Molecularly, four had biallelic inactivation and six had bZIP mutations. The high mortality among non-transplanted patients may suggest an aggressive nature of CEBPA-mutated MPAL, even in those with bZIP mutations, unlike its favorable-risk status in AML. Given the small sample and biases, no conclusions regarding optimal post-remission therapy can be drawn, though intensive strategies including transplantation may be considered based on this aggressiveness.

Indexed as

Allogeneic hematopoietic stem cell transplantationbZIP domainCEBPA mutationMixed phenotype acute leukemia

Identifiers

PMID42687201
PMCPMC13536837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.